Annales pharmaceutiques francaises · 2026
[Securing the administration of anesthestetics with the implementation of NRFIT connectors: Experience in a French University Hospital].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Garbil Eva, Drouin-Bonnet Arthur, Kerhoas Anne, Gasnier Fabrice, Armoiry Xavier
Аннотация
OBJECTIVES: This study reports the experience of a French university hospital transitioning from Luer connectors to the secure NRFIT standard for neuraxial applications, with the aim to prevent serious drug administration errors. The objective was to describe the project approach, to share feedback, and to provide a preliminary evaluation of the economic impact.
METHODS: A multidisciplinary project group involving pharmacy and anesthesiology-critical care departments was established. The process included an exhaustive inventory and rationalisation of Luer medical devices (MD), followed by identification and validation of equivalent NRFIT devices through technical reviews and bench testing. The deployment was carefully planned using a Gantt chart, supported by an internal communication and training plan, and included a temporary three-month buffer stock of NRFIT devices. A post-transition analysis assessed the costs of withdrawn Luer stock and compared procurement costs between NRFIT and Luer systems.
RESULTS: Of a total of 65 preexisting references of MDs, 44 were retained then converted to a NRFIT equivalent reference during a two-phase rollout in July and August 2025, driven by supplier availability. Multidisciplinary coordination and detailed planning were key success factors. Challenges included supply delays and the management of patients transferred from other hospitals equipped with Luer devices, requiring specific protocols. The transition resulted in a net loss of €7,873 from withdrawn Luer stock and a provisional annual cost increase of €11,224.
CONCLUSIONS: The transition to NRFIT connectors was feasible and safe despite organisational and financial constraints. Strong multidisciplinary leadership, careful planning, effective communication, and training were essential. Wider adoption of NRFIT devices across hospitals may help reduce additional purchasing costs.
METHODS: A multidisciplinary project group involving pharmacy and anesthesiology-critical care departments was established. The process included an exhaustive inventory and rationalisation of Luer medical devices (MD), followed by identification and validation of equivalent NRFIT devices through technical reviews and bench testing. The deployment was carefully planned using a Gantt chart, supported by an internal communication and training plan, and included a temporary three-month buffer stock of NRFIT devices. A post-transition analysis assessed the costs of withdrawn Luer stock and compared procurement costs between NRFIT and Luer systems.
RESULTS: Of a total of 65 preexisting references of MDs, 44 were retained then converted to a NRFIT equivalent reference during a two-phase rollout in July and August 2025, driven by supplier availability. Multidisciplinary coordination and detailed planning were key success factors. Challenges included supply delays and the management of patients transferred from other hospitals equipped with Luer devices, requiring specific protocols. The transition resulted in a net loss of €7,873 from withdrawn Luer stock and a provisional annual cost increase of €11,224.
CONCLUSIONS: The transition to NRFIT connectors was feasible and safe despite organisational and financial constraints. Strong multidisciplinary leadership, careful planning, effective communication, and training were essential. Wider adoption of NRFIT devices across hospitals may help reduce additional purchasing costs.